New temperate DNA phage BcP15 acts as a drug resistance vector.
This study was designed to determine the role of a new temperate DNA phage BcP15 in relation to drug resistance. The multidrug resistant Shigella flexneri NK1925 was isolated from a patient of Infectious Diseases Hospital, Kolkata, India. This strain contained five plasmids ranging in size from 3 to 212 kb. After curing of five plasmids, this strain became sensitive to antibiotics. A plasmidless multidrug-resistant strain Burkholderia cepacia DR11 was isolated during the survey of microorganisms from coastal waters of deltaic Sunderbans. This strain always released a temperate phage BcP15 into culture supernatant. Turbid plaque formation was observed on the lawn of a plasmidless version (Pl(-)35) of Shigella flexneri NK1925. A few distinct clones (Pl(-)35R) appeared within the region of each plaque after 18 h incubation. S. flexneri NK1925, Pl(-)35, and Pl(-)35R clones showed the same PFGE band pattern of XbaI-digested chromosomal DNA. However, Pl(-)35R clones were resistant to co-trimoxazole, trimethoprim, and eryth- romycin, to which B. cepacia DR11 was also resistant. Southern hybridization results indicated that these three antibiotic resistances in Pl(-)35R clones were due to a BcP15 phage lysogen in the Pl(-)35 version of S. flexneri NK1925.
Hens
D K
DK
Sonamukhi College, Sonamukhi, Bankura, India.
Chatterjee
N C
NC
Kumar
R
R
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001435:Bacteriophages / Q000235:genetics*; D015139:Blotting, Southern; D016956:Burkholderia cepacia / Q000187:drug effects / Q000821:virology*; D016172:DNA Fingerprinting; D004269:DNA, Bacterial / Q000235:genetics; D004279:DNA, Viral / Q000032:analysis; D015252:Deoxyribonucleases, Type II Site-Specific; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D004405:Dysentery, Bacillary / Q000382:microbiology; D016521:Electrophoresis, Gel, Pulsed-Field; D004917:Erythromycin / Q000494:pharmacology; D022761:Gene Transfer, Horizontal; D006801:Humans; D007194:India; D010957:Plasmids / Q000235:genetics; D012150:Polymorphism, Restriction Fragment Length; D039002:Prophages / Q000235:genetics*; D012763:Shigella flexneri / Q000187:drug effects / Q000302:isolation & purification / Q000821:virology*; D014295:Trimethoprim / Q000494:pharmacology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology; D010948:Viral Plaque Assay
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D004279:DNA, Viral; D004917:Erythromycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; C025580:endodeoxyribonuclease XBAI; D015252:Deoxyribonucleases, Type II Site-Specific